It was demonstrated that CTRP12 mitigated de novo atherosclerosis by enhancing reverse cholesterol transport efficiency and suppressing vascular inflammation via the miR‐155‐5p/LXRβ pathway, indicating that CTRP12 was associated with ISR occurrence in CAD after PCI treatment [11]. This evidence concerns the gene C1QTNF12 and atherosclerosis.